CSL Behring to discontinue plasma-derived therapy for hemophilia B

CSL Behring has announced the discontinuation of its plasma-derived factor IX concentrate Mononine®, used in the treatment and prevention of bleeding in hemophilia B, citing declining demand in recent years due to the availability of newer, next generation treatment options. Mononine® was among the earliest high-purity factor concentrates when introduced in 1992. CSL Behring expects product supply will be available until June 2021. The company began notifying patient organizations, healthcare providers and patients in mid-September to provide ample time for consideration and selection of alternative treatment options.